This is a bulk, in-vivo-ready preparation of the LO-CD2a clone, a rat IgG2b, kappa monoclonal antibody raised against human CD2. The rat IgG2b isotype and defined specificity make it well suited to functional and mechanistic studies where reproducible, lot-consistent reagent is required at scale. LO-CD2a is a widely referenced anti-human CD2 clone with documented immunomodulatory activity, validated here for ELISA, functional assays, and flow cytometry. Because it targets a human antigen, it is typically deployed in humanized-mouse and xenograft systems, ex-vivo human cell assays, and functional T-cell/NK-cell studies rather than conventional immunocompetent mouse models. The product is supplied at low endotoxin (research grade <1 EU/mg; ultra-low <0.5 EU/mg) to minimize confounding innate activation in functional and in-vivo work, and in bulk milligram-to-gram quantities to support dose-ranging, repeat-dosing, and larger cohort studies. All material is for research use only (RUO). Researchers most often source this reagent by clone name (LO-CD2a) when reproducing or extending published functional CD2-targeting protocols.
CD2 (UniProt P06729; also known as LFA-2 or the SRBC/E-rosette receptor) is a ~50 kDa type I transmembrane glycoprotein of the immunoglobulin superfamily expressed predominantly on T cells and natural killer (NK) cells, with expression rising during T-cell maturation. Its principal ligand in humans is CD58 (LFA-3), and CD2-CD58 engagement contributes to adhesion between T cells or NK cells and antigen-presenting or target cells while delivering costimulatory signals that lower the threshold for TCR-driven activation. The cytoplasmic tail couples to intracellular signaling adaptors that reinforce proximal TCR signaling, proliferation, and cytokine production. Because CD2 is highly restricted to and functionally important in T and NK compartments, and because activated and memory effector cells can express elevated CD2, it is an attractive target for modulating or depleting pathogenic lymphocytes in transplantation, autoimmunity, and immuno-oncology contexts.